Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	94379
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Rui Zhang, Yan-Hui Liu, Yu Li, Nan-Nan Li and Zheng Li
Funding Agency and Grant Number	Funding Agency Grant Number The National Natural Science Foundation of China No. 82104525 The Natural Science Foundation of the Jiangsu Higher Education Institutions of China No. 21KJB360009
Corresponding Author	Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Key Words	Transarterial chemoembolization; Multi-targeted tyrosine kinase inhibitor; Programmed cell death protein-1 inhibitor; Unresectable hepatocellular carcinoma; Mechanism
Core Tip	This editorial focuses on the mechanisms for combining transarterial chemoembolization with multi-targeted tyrosine kinase inhibitor and programmed cell death protein-1 inhibitor for unresectable hepatocellular carcinoma, administration sequence and selection of each medication, and implications for future clinical trials. Despite several retrospective trials have evaluated the efficacy and safety of this triple therapy, the flawed study design and heterogeneity in medications still arise controversial concerns on the results. Especially, the administration sequence between each medication varied across trials, which could greatly affect the clinical benefit. So, the administration sequence needs to be fully considered in future trials based on the interaction mechanisms between each medication.
Citation	<p>Zhang R, Liu YH, Li Y, Li NN, Li Z. Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma. <i>World J Gastrointest Oncol</i> 2024; 16(11): 4315-4320</p>

Received	2024-03-18 14:22
Peer-Review Started	2024-03-18 14:22
To Make the First Decision
Return for Revision	2024-06-26 06:32
Revised	2024-07-01 13:44
Second Decision	2024-07-09 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-07-09 06:55
Articles in Press	2024-07-09 06:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-07-29 01:41

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https: //creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com